心力衰竭中的生物标志物:聚焦利钠肽
本文综述利钠肽(NPs)的生理学与生物学效应,并讨论其在心力衰竭诊断、管理和预后评估中的作用,以及作为潜在治疗剂的可能性。文章指出心衰在英国影响约百万人且预后差,及时诊断与启动循证治疗是改善结局的关键。
要点
- 利钠肽是心衰研究最充分的生物标志物,已成为日常临床诊断与预后评估的重要工具。
- 心衰患者常为老年且合并复杂共病,准确评估具有挑战性,及时诊断与循证治疗可预防住院并改善结局。
- 利钠肽自1980年代发现以来研究大量涌现,其作为潜在治疗剂的作用也在探索中。
核心结论
- 利钠肽是心衰诊断、管理和预后评估的重要临床工具,并可能作为潜在治疗剂。
研究设计与样本
- 综述文章,回顾利钠肽的生理学与生物学效应及其在心衰诊断、管理和预后评估中的作用。
主要发现
- 心衰在英国影响约百万人,预后比大多数癌症更差。
- 心衰患者常为老年且合并复杂共病,使准确评估具有挑战性。
- 利钠肽自1980年代发现以来研究大量涌现,已成为日常实践中的重要临床工具。
临床怎么用
- 利钠肽可用于指导心衰患者的诊断与预后评估。
- 及时诊断和启动循证治疗是预防住院和改善心衰人群结局的关键。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While progress has been made in the management of most aspects of cardiovascular disease, the incidence and prevalence of heart failure (HF) remains high. HF affects around a million people in the UK and has a worse prognosis than most cancers. Patients with HF are often elderly with complex comorbidities, making accurate assessment of HF challenging. A timely diagnosis and initiation of evidence-based treatments are key to prevent hospitalisation and improve outcomes in this population. Biomarkers have dramatically impacted the way patients with HF are evaluated and managed. The most studied biomarkers in HF are natriuretic peptides (NPs). Since their discovery in the 1980s, there has been an explosion of work in the field of NPs and they have become an important clinical tool used in everyday practice to guide diagnosis and prognostic assessment of patients with HF. In this article, we will review the physiology of NPs and study their biological effects. Then, we will discuss the role of NPs in the diagnosis, management and prognostication of patients with HF. We will also explore the role of NPs as a potential therapeutic agent.
引用
- Eltayeb, Squire, Sze, et al. Biomarkers in heart failure: a focus on natriuretic peptides. Heart. 2024. PMID: 37673654. doi:10.1136/heartjnl-2020-318553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。